28959956|t|ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
28959956|a|APOE4 is the strongest genetic risk factor for late-onset Alzheimer disease. ApoE4 increases brain amyloid-beta pathology relative to other ApoE isoforms. However, whether APOE independently influences tau pathology, the other major proteinopathy of Alzheimer disease and other tauopathies, or tau-mediated neurodegeneration, is not clear. By generating P301S tau transgenic mice on either a human ApoE knock-in (KI) or ApoE knockout (KO) background, here we show that P301S/E4 mice have significantly higher tau levels in the brain and a greater extent of somatodendritic tau redistribution by three months of age compared with P301S/E2, P301S/E3, and P301S/EKO mice. By nine months of age, P301S mice with different ApoE genotypes display distinct phosphorylated tau protein (p-tau) staining patterns. P301S/E4 mice develop markedly more brain atrophy and neuroinflammation than P301S/E2 and P301S/E3 mice, whereas P301S/EKO mice are largely protected from these changes. In vitro, E4-expressing microglia exhibit higher innate immune reactivity after lipopolysaccharide treatment. Co-culturing P301S tau-expressing neurons with E4-expressing mixed glia results in a significantly higher level of tumour-necrosis factor-alpha (TNF-alpha) secretion and markedly reduced neuronal viability compared with neuron/E2 and neuron/E3 co-cultures. Neurons co-cultured with EKO glia showed the greatest viability with the lowest level of secreted TNF-alpha. Treatment of P301S neurons with recombinant ApoE (E2, E3, E4) also leads to some neuronal damage and death compared with the absence of ApoE, with ApoE4 exacerbating the effect. In individuals with a sporadic primary tauopathy, the presence of an epsilon4 allele is associated with more severe regional neurodegeneration. In individuals who are positive for amyloid-beta pathology with symptomatic Alzheimer disease who usually have tau pathology, epsilon4-carriers demonstrate greater rates of disease progression. Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-beta pathology. ApoE4 exerts a 'toxic' gain of function whereas the absence of ApoE is protective.
28959956	40	57	neurodegeneration	Disease	MESH:D019636
28959956	63	68	mouse	Species	10090
28959956	78	87	tauopathy	Disease	MESH:D024801
28959956	147	164	Alzheimer disease	Disease	MESH:D000544
28959956	229	233	ApoE	Gene	348
28959956	261	265	APOE	Gene	348
28959956	322	335	proteinopathy	Disease	MESH:D057165
28959956	339	356	Alzheimer disease	Disease	MESH:D000544
28959956	367	378	tauopathies	Disease	MESH:D024801
28959956	396	413	neurodegeneration	Disease	MESH:D019636
28959956	443	448	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	464	468	mice	Species	10090
28959956	481	486	human	Species	9606
28959956	487	491	ApoE	Gene	348
28959956	509	513	ApoE	Gene	348
28959956	558	563	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	567	571	mice	Species	10090
28959956	718	723	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	728	733	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	742	747	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	748	751	EKO	CellLine	
28959956	752	756	mice	Species	10090
28959956	781	786	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	787	791	mice	Species	10090
28959956	807	811	ApoE	Gene	348
28959956	893	898	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	902	906	mice	Species	10090
28959956	929	942	brain atrophy	Disease	MESH:C566985
28959956	947	964	neuroinflammation	Disease	MESH:D000090862
28959956	970	975	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	983	988	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	992	996	mice	Species	10090
28959956	1006	1011	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	1012	1015	EKO	CellLine	
28959956	1016	1020	mice	Species	10090
28959956	1143	1161	lipopolysaccharide	Chemical	MESH:D008070
28959956	1186	1191	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	1318	1327	TNF-alpha	Gene	21926
28959956	1455	1458	EKO	CellLine	
28959956	1528	1537	TNF-alpha	Gene	21926
28959956	1552	1557	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
28959956	1583	1587	ApoE	Gene	348
28959956	1620	1645	neuronal damage and death	Disease	MESH:D009410
28959956	1675	1679	ApoE	Gene	348
28959956	1748	1765	primary tauopathy	Disease	MESH:D024801
28959956	1842	1859	neurodegeneration	Disease	MESH:D019636
28959956	1937	1954	Alzheimer disease	Disease	MESH:D000544
28959956	2084	2088	ApoE	Gene	348
28959956	2115	2132	neuroinflammation	Disease	MESH:D000090862
28959956	2151	2168	neurodegeneration	Disease	MESH:D019636
28959956	2273	2277	ApoE	Gene	348
28959956	Association	MESH:D009410	348
28959956	Positive_Correlation	MESH:D000090862	HGVS:p.P301S;CorrespondingGene:348
28959956	Positive_Correlation	MESH:C566985	HGVS:p.P301S;CorrespondingGene:348
28959956	Association	MESH:D000090862	348
28959956	Association	MESH:C566985	348

